BCG036 / Biocytogen - LARVOL DELTA

A half-life extended PD-1×VEGFA bispecific antibody demonstrates potent anti-tumor activity in preclinical models (AACR 2026) - "VEGF-A inhibition (e.g., bevacizumab) normalizes tumor vasculature, enhancing immune cell delivery and synergizing with PD-1 inhibitors. Importantly, BCG036 displayed a favorable safety and PK profile in cynomolgus monkeys after repeated dosing at 100 mg/kg.Conclusions Our prolonged half-life version of the PD-1×VEGF-A bispecific antibody shows high affinity in vitro and has a strong ability to block the interactions of PD-1/PD-L1 and VEGFR2/VEGFA. It demonstrates strong antitumor activity in mouse models and has demonstrated good safety in cynomolgus monkeys, supporting a long-term dosing regimen."

Bispecific • Preclinical • Oncology • KDR • PD-1